Israel-based clinical research and analytics technology provider Zebra Medical Vision received $30m in a series C round yesterday from investors including health system Intermountain Healthcare and pharmaceutical firm Johnson & Johnson.
The round was led by AMoon Ventures, with participation from semiconductor and consumer electronics company Nvidia and Johnson & Johnson Innovation – JJDC, the corporate venturing arm of pharmaceutical firm Johnson & Johsnon.
Khosla Ventures, OurCrowd, Dolby Family Ventures and assorted angel investors also took part.
Founded in 2014, Zebra has developed an imaging analytics platform that relies on machine and deep learning to help identify patients at risk of disease. The company is also working on automated chest x-ray analysis using artificial intelligence.
The company has received regulatory approval in Europe as well as several Latin American and Asian countries for a seven of its tools, including mammography lesion detection algorithms.
Nvidia previously revealed an investment in Zebra in May 2017, though it is unclear if that commitment was separate to the series C round.
Intermountain led a $12m round for Zebra in 2016 that also featured unnamed, existing backers. Zebra had previously raised $8m from Khosla and DeepFork Capital, as well as Marc Benioff, as of April 2015.
OurCrowd and Dolby were identified as returning investors for the series C round, but details about their previous involvement could not be ascertained.